Innate Pharma to present lacutamab PTCL Phase 1b design and ANKET platform at ESMO 2022

Poster presentation on ongoing lacutamab Phase 1b trial design in monotherapy in peripheral T-cell lymphoma Oral presentation on multispecific antibodies: ANKET for antigen-specific activation of NK cells by Innate’s Chief Scientific Officer, Eric Vivier, DVM, PhD, AstraZeneca-sponsored Phase 2 NeoCOAST study of neoadjuvant durvalumab alone or combined with novel agents, including monalizumab, in patients with resectable, early-stage non-small cell lung cancer (NSCLC) accepted for a mini-oral presentation on pharmacodynamic and circulating tumor DNA dynamics in the study Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that the following presentations will be presented at the ESMO (European Society for Medical Oncology) Annual Meeting 2022 taking place from 9 to 13 September 2022, in Paris, France. A multi-center Phase Ib trial evaluating the safety and efficacy of lacutamab in patients with relapsed/refractory peripheral T-cell lymphoma that express KIR3DL2 Abstract Number: 647TiP Session Type: Trial In Progress Poster Session Title: Haematological malignancies Session Date: Sunday Sept 11, 2022 Presenter: Marianna Muller, MD, PharmD, Clinical Development Director at Innate Pharma Oral presentation: Designing multispecific antibodies: ANKET for antigen-specific activation of NK cells Session Type: Special session Session Title: Next frontiers in drug discoveries Date and Time: Monday Sept 12, 2022 9:05 AM - 9:20 AM CEST Location: 7.3.U - Urval Auditorium Presenter: Eric Vivier, DVM, PhD, Chief Scientific Officer of Innate Pharma Oral presentation: Platform study of neoadjuvant durvalumab (D) alone or combined with novel agents in patients (pts) with resectable, early-stage non-small-cell lung cancer (NSCLC): pharmacodynamic correlates and circulating tumor DNA (ctDNA) dynamics in the NeoCOAST study [AstraZeneca-sponsored] Presentation #929MO Session Type: Mini Oral Session Session Title: Non-metastatic NSCLC and other thoracic malignancies Date and Time: Monday Sept 12, 2022 3:15 PM CEST Location: 7.3.O - Orléans Auditorium Presenter: Jonathan Spicer (Montreal, Canada) The poster and presentations will be available on the Publications section of innate-pharma.com following the presentation. Subscribe to our newsletter Contact us 117, Avenue de Luminy - BP 30191 13 009 Marseille FRANCE +33 (0)4 30 30 30 30

The release as fetched from its publisher. innate-pharma.com ↗